Home › Interstitial Lung Diseases › Virginia
Interstitial Lung Diseases clinical trials in Virginia
8 studies for Interstitial Lung Diseases are looking for participants at sites in Virginia.
Cities in Virginia
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Virginia Commonwealth University, Richmond
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 30, 2026 · NCT07201922Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA008, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07179380Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Virginia Commonwealth University, Richmond
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Inova Medical Group, Falls Church
- Sentara Norfolk General Hospital, Norfolk
- Pulmonary Associates of Richmond, Inc., Richmond
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Virginia, Charlottesville
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Aug 18, 2026 · NCT06855329Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Inova, Falls Church
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- University of Virginia Health System, Charlottesville
- Christopher King, MD, Falls Church
- Pulmonary Associates of Richmond, Inc., Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.